Andrew Huberman· PhD
Now, you mentioned that as people enter these psychedelic states, that there's a little bit of initial anxiety. About a year and a half ago, I had a discussion with Dr. Matthew Johnson who's running some psilocybin trials at Johns Hopkins, as you know. And he mentioned the critical importance, at least in his mind, to this idea of the patient, quote unquote, "letting go" or allowing the experience to take them someplace mentally as opposed to trying to constrain their sensory and cognitive experience.